Results 161 to 170 of about 2,148,975 (183)

The new biology of PTCL‐NOS and AITL: current status and future clinical impact

British Journal of Haematology, 2020
SummaryPeripheral T‐cell lymphomas (PTCL) comprise a heterogeneous group of aggressive lymphoproliferative disorders almost all of which are associated with poor clinical outcomes. Angioimmunoblastic T‐cell lymphoma (AITL) and some peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS) have similarities to normal CD4+ T‐cell subsets in their ...
Simon D Wagner, Matthew J Ahearne
exaly   +3 more sources

Sub-acute Demyelinating Polyradiculoneuropathy as an Initial Symptom of Peripheral T Cell Lymphoma, Not Otherwise Specified (PTCL-NOS)

Internal Medicine, 2012
Here we report the first case of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), who initially presented with peripheral neuropathy. Nerve conduction, cerebral spinal fluid studies and his clinical course were compatible with sub-acute demyelinating polyradiculoneuropathy.
Hirokazu Tanaka, Junichi Miyatake, Takashi Ashida   +2 more
exaly   +4 more sources

Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS

Annals of Hematology, 2023
Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS), is a heterogeneous and aggressive type of non-Hodgkin's lymphoma with a bleak prognosis. This study was designed to assess the value of EFS24 as an alternative clinical endpoint and identify prognosis-related factors in PTCL, NOS.
Zheng Cao, Xiaojun Wang, Xuemin Xue, Xiaoli Feng   +3 more
openaire   +2 more sources

16. Molecular pathogenesis of malignant lymphomas: PTCL, NOS and AITL

2016
Adolfo A Ferrando, TERESA Palomero
exaly   +2 more sources

FOXP3(+) PTCL-NOS: a clinical and pathological analysis of 10 cases

Pathology, 2014
Treg phenotype of CD4+CD25+FOXP+ was almost exclusively reported in ATLL. However, this phenotype has not been well addressed on PTCL-NOS, because of the rarity, and its clinico-pathological characteristics still remain unknown. Here, we report 10 cases of FOXP3(+) PTCL-NOS with Treg phenotype.
Akira Satou, Seiichi Kato, Naoko Asano, Shigeo Nakamura   +3 more
openaire   +1 more source

GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features

Blood, 2014
Key Points Alternatively polarized macrophages are abundant constituents of the tumor microenvironment in T-cell lymphoproliferative disorders. GATA-3 expression identifies a subset of PTCL, NOS with a distinct cytokine profile and inferior survival.
David A Wada, Robert Briski, Kay Ristow   +2 more
exaly   +4 more sources

The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL

Blood, 2015
Abstract Purpose: We assessed the survival outcome of patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) who experienced disease progression or relapse after first line and subsequent therapy.
Dai Chihara, Michelle A. Fanale, Mansoor Noorani, Jason R Westin, Loretta Nastoupil, Fredrick B. Hagemeister, Luis E. Fayad, Jorge E. Romaguera, Felipe Samaniego, Francesco Turturro, Hun Ju Lee, Sattva S. Neelapu, Alma Rodriguez, Michael Wang, Nathan Fowler, Roberto N. Miranda, Chitra M. Hosing, Yago Nieto, Richard Eric Davis, Yasuhiro Oki   +19 more
openaire   +1 more source

The role of ENO1 and chidamide in PTCL-NOS

Blood
Abstract Enolase (ENO1) is a key enzyme involved in glycolysis and plays an important role in various types of cancer. This study explored the role and mechanism of ENO1 and the histone deacetylase inhibitor chidamide in peripheral T cell lymphoma, not otherwise specified (PTCL-NOS).
Mingxi Tian, Jiao Liu, Xuejiao Gu, Bin Lv, Zhenyu Li, Kailin Xu, Feng Zhu   +6 more
openaire   +1 more source

PDGFRA Activity Is Mediated by An Autocrine Loop in Peripheral T-Cell Lymphoma/Not Otherwise Specified (PTCL/NOS).

Blood, 2009
Abstract Abstract 4631 Background Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of tumors representing approximately 12% of lymphoid neoplasms, basically subdivided into specified and not specified (NOS) forms. PTCL/NOS, corresponding to about 60%–70% of PTCLs, cannot be
Maura Rossi, Francesco Alviano, Antonella Laginestra, Pierluigi Tazzari, Francesca Ricci, Aurora Esposito, Claudio Agostinelli, Maria Teresa Sista, Anna Gazzola, Claudia Mannu, Simona Righi, Maria Rosaria Sapienza, Gian Paolo Bagnara, Sylvia Hartmann, Martin Leo Hansmann, Pier Luigi Zinzani, Stefano Aldo Pileri, Pier Paolo Piccaluga   +17 more
openaire   +1 more source

Cavitary Lymphoma: A Rare Case of a Necrotizing Pulmonary PTCL-NOS in a Young Hispanic Woman

American Journal of Respiratory and Critical Care Medicine
Abstract Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), is a rare and aggressive subtype of non-Hodgkin lymphoma that typically presents in adults between the ages of 55-75. Presentation usually involves multi-organ infiltration and diffuse lymphadenopathy.
J. Lopez Ventosa, N. Garcia, R. Muñoz, R. Gonzalez Toledo, J. Nieves Rivera   +4 more
openaire   +1 more source